PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Oct 22, 2012
SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue fever, a mosquito-borne disease that is a ...
Sep 28, 2012
SOUTH PLAINFIELD, NJ – September 28, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation in Summit, New Jersey. "We are ...
Jul 23, 2012
SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing inv...
Jul 11, 2012
SOUTH PLAINFIELD, NJ – July 11, 2012 – PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and drug-resistant tumors. The milestone triggers drawdown of the next $2.3 million installment of its Seeding Drug Discovery Award from the Wellcome Trust....
Jun 27, 2012
SOUTH PLAINFIELD, NJ – June 27, 2012 – PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior, PTC-sponsored clinical study. The primary objective ...
Jun 8, 2012
SOUTH PLAINFIELD, NJ – June 8, 2012 – PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The results demonstrated positive trends in lung function as measured by FEV1 (forced expiratory volume in one second) and in the...
Apr 2, 2012
SOUTH PLAINFIELD, NJ – April 2, 2012 - PTC Therapeutics, Inc. (PTC) today announced the promotions of Cláudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer."I am extremely pleased to announce these promotions. Cláudia has made significant contributions to the growth and development of PT...
Dec 22, 2011
SOUTH PLAINFIELD, NJ – December 22, 2011 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. PTC previousl...
Nov 29, 2011
Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme. SMA is a genetic neuromuscular disorder that causes muscle weakness. One in every 10,000 children born is affected with the disorder, which currently has no effective treat...
Nov 7, 2011
South Plainfield, NJ– November 7, 2011 - PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges. Dr. Zhengxian Gu...
Page: FirstPrevious ...
21
NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue